Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool

Tocilizumab (TCZ), an IL-6 receptor blocker, is approved for relapsing, refractory giant cell arteritis (GCA). We report real-life clinical experience with TCZ in GCA including assessment of responses on imaging (ultrasound (US) and 18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomogr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebastian, Alwin, Kayani, Abdul, Prieto-Pena, Diana, Tomelleri, Alessandro, Whitlock, Madeline, Mo, Jonathan, van der Geest, Niels, Dasgupta, Bhaskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Vasculitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856116/
https://www.ncbi.nlm.nih.gov/pubmed/33161376
http://dx.doi.org/10.1136/rmdopen-2020-001417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856116/
https://www.ncbi.nlm.nih.gov/pubmed/33161376
http://dx.doi.org/10.1136/rmdopen-2020-001417

Ejemplares similares